Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 24th Congress of EHA, abstract LB2606.
Derde generatie anti-CD19 CAR T-cellen voor gerecidiveerde/refractaire CLL
jan 2025 | Leukemie, Lymfoom